NCT00082212View on ClinicalTrials.gov

A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Ovarian Cancer
Interventions
BIOLOGICAL

Cetuximab

400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles

Trial Locations (5)

10021

ImClone Investigational Site, New York

19111

ImClone Investigational Site, Philadelphia

32804

ImClone Investigational Site, Orlando

35233

ImClone Investigational Site, Birmingham

09104

ImClone Investigational Site, Seattle

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY